Connect patients to Velphoro with Velphoro Access Solutions

More patients than ever have access to Velphoro through their commercial and Medicare Part D pharmacy benefit plans
Most patients pay less than $10/month for Velphoro

Find out more about Velphoro Access Solutions

GET the application

Velphoro Access Solutions can help you get new patients started

Top commercial and Medicare Part D plans cover Velphoro. If prior authorization (PA) is required by the patient’s insurance plan, a case manager is available to help and will automatically initiate the PA.¹

GET the application

Choose the pathway to Velphoro most appropriate for your patients.

Commercial insurance pathways

For all patients with commercial insurance

Velphoro Savings Card program*^†‡
- Who’s eligible: Patients with commercial insurance with copay, coinsurance, or a deductible*
- How they can benefit: 96% of patients who redeem the Velphoro Savings Card pay $0 for Velphoro¹
GET THE SAVINGS CARD
Assistance for eligible patients
- For commercially insured patients with household income between 1.5—4.5 times the Federal poverty limit, up to $117,900 for a family of four²
- Patients are automatically referred if their out-of-pocket costs are >$50*
Get the application

Medicare Part D Standard/LIS pathways

For patients on Medicaid and/or Low Income Subsidy (LIS) Extra Help

Help patients enroll at ssa.gov
- Most patients pay ≤$8.95 per monthly prescription^§3

For patients on Medicare Part D Standard and/or

Household income between 1.5—4.5 times the federal poverty limit, up to $117,900 for a family of four²
Out-of-pocket costs >$50
- Patient Assistance Program PAP: Fill out PAP application provided in benefit summary and obtain patient signature

New to dialysis

For patients who are new to dialysis and have a Medicare application pending within 90 days
- Velphoro Bridge Program: Up to 90 days of Velphoro at no cost: Call Velphoro Access Solutions at 877-774-6756

INDICATION

Velphoro^® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

IMPORTANT SAFETY INFORMATION

Velphoro chewable tablets must be administered with meals. Velphoro should be chewed or crushed. Do not swallow whole.
Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal (GI) surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.
In a parallel design, fixed-dose study of 6 weeks duration, the most common adverse drug reactions to Velphoro chewable tablets in hemodialysis patients included discolored feces (12%) and diarrhea (6%).
Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. For oral medications where a reduction of bioavailability would be clinically significant consider separating of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medications.

For additional important safety information, please see the full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care North America at 1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is intended for use by US healthcare professionals only.

Distributed by:
Fresenius Medical Care North America
Waltham, MA 02451